NEW YORK, Dec. 16 (GenomeWeb News) - Advion BioSciences said today that it has signed a three-year mass spectrometry services contract worth $9 million with an undisclosed "top-10 pharmaceutical company."
Advion will provide scientists and instrumentation to support the pharmaceutical client's bioanalytical method development, method validation, and sample analysis programs, the company said.
The agreement also provides the client an option to increase its level of resources during the life of the contract.
Stephen Lowes, Advion's vice president of bioanalysis, called the deal the "first of its kind" for the company. "The contract offers a resource model that could be extended to other clients in an environment where top-tier bioanalytical experience is in high demand," he said.